The influence of Ki-67 proliferation index on Tc-99m-EDDA-HYNIC-TOC somatostatin receptor scintigraphy in patients with carcinoids

• Autorzy: Marina Vlajković , Milena Rajić , Slobodan Ilić , Miloš Stević , Marko Kojić , Vesna Živković , Aleksandar Karanikolić , Milovan Matović
• Języki publikacji: EN

Abstrakty

EN

The aim of this paper is to determine the influence of Ki-67 proliferation index on somatostatin receptor scintigraphy (SSRS) with Tc-99m-EDDA-HYNIC-TOC (Tc-99m-Tektrotyd) somatostatin analogue in patients with carcinoid tumors. Sixty-one patients (31 female, 30 male; age range: 33-76 years) were examined: 13 patients highly suspected of having a carcinoid, and 48 patients who had undergone the surgical removal of the tumor. Whole body SSRS at 4 h postinjection, spot scintigrams and SPECT of the selected regions were obtained for all patients. Tc-99m-Tektrotyd scintigraphy was classified as true positive in 26 out of 30 and true negative in 24 out of 28 patients. The sensitivity of Tc-99mTc-Tektrotyd scintigraphy was found to be as high as 94.74% in the group of patients with low mitotic index Ki67 (<2%), and it progressively decreased in patients with higher mitotic index (77.78% for Ki67 2-15% and 20% for Ki67% >20%). The likelihood of Tc-99m-Tektrotyd scan being positive when a carcinoid is present was found to be inversely proportional to the value of Ki67 proliferation index. The results showed that Tc-99m-Tektrotyd SSRS is a sensitive method for diagnosing and staging patients with well-differentiated carcinoid tumors. However, in poorly differentiated tumors with high Ki67 proliferation index, additional analyses are necessary for precise staging.

Słowa kluczowe

EN

carcinoid tumor; somatostatin receptor scintigraphy; proliferation index Ki67

• Czasopismo: Open Chemistry
• Rocznik: 2015
• Tom: 13
• Numer: 1

Daty

otrzymano

2014-02-28

zaakceptowano

2014-06-30

online

2014-11-26

Twórcy

autor

Marina Vlajković

• Faculty of Medicine, Center of Nuclear Medicine, Clinical Center Niš, 18000 Niš, Serbia

autor

Milena Rajić

• Faculty of Medicine, Center of Nuclear Medicine, Clinical Center Niš, 18000 Niš, Serbia

autor

Slobodan Ilić

• Faculty of Medicine, Center of Nuclear Medicine, Clinical Center Niš, 18000 Niš, Serbia

autor

Miloš Stević

• Faculty of Medicine, Center of Nuclear Medicine, Clinical Center Niš, 18000 Niš, Serbia

autor

Marko Kojić

• Faculty of Medicine, Center of Nuclear Medicine, Clinical Center Niš, 18000 Niš, Serbia

autor

Vesna Živković

• Faculty of Medicine, Clinic of Physical Medicine, Rehabilitation and Prosthetics, Clinical Center Niš, 18000 Niš, Serbia

autor

Aleksandar Karanikolić

• Faculty of Medicine, Clinic for Surgery, Clinical Center Niš, 18000 Niš, Serbia

autor

Milovan Matović

• Faculty of Medicine, Center of Nuclear Medicine, Clinical Center Kragujevac, 34000 Kragujevac, Serbia

Bibliografia

• [1] Modlin I.M., et al., Lancet. Oncol., 2008, 9, 61[Crossref]
• [2] Koopmansa K.P., et al., Critical Reviews in Oncology/Hematology, 2009, 71, 199
• [3] Pearse A.G.E,, In: Frisen S.R., Thompson N.W. (Eds.), Surgical endocrinology, Lippincott, Philadelphia, 1990, 25
• [4] Solcia E., Klöppel G., Sobin L.H., Histological typing of endocrine tumours, 2nd edition, Springer, Berlin, 2000
• [5] Pelosi G., et al., Hum. Pathol., 1996, 27, 1124[Crossref]
• [6] Kaltsas G., et al., Eur. J. Endocrin., 2004, 151, 15[Crossref]
• [7] Leboulleux S., et al., J. Clin. Endocrinol. Metab., 2008, 93, 3021[Crossref]
• [8] Binderup T., et al., Neuroendocrinology, 2008, 87, 223[Crossref]
• [9] Reubi J.C., Waser B., Schaer J.C., Laissue J.A., Eur. J. Nucl. Med., 2001, 28, 836[Crossref]
• [10] Koopmans K.P., et al., Crit. Rev. Oncol. Hematol., 2009, 71, 199[Crossref]
• [11] Raderer M., et al., .J Clin. Oncol., 2000, 18, 1331[Crossref]
• [12] Ezziddin S., et al., J. Nucl. Med., 2006, 47, 223
• [13] Von Moll L., et al., J. Nucl. Med., 1987, 28, 979
• [14] Koopmans K.P., et al., J. Clin. Oncol., 2008, 26, 1489[Crossref]
• [15] Koopmans K.P., et al., Lancet. Oncol., 2006, 7, 728[Crossref]
• [16] Buchmann I., et al., Eur. J. Nucl. Med. Mol. Imaging., 2007, 34, 1617[Crossref]
• [17] Adams S., et al., Nucl. Med. Commun., 1998, 19, 641[Crossref]
• [18] Belhocine T., et al., Nucl. Med. Commun., 2002, 23, 727[Crossref]
• [19] Kayani I., et al., Cancer, 2008, 112, 2447[Crossref]
• [20] Klopel G., Perren A., Heitz P.U., Ann. N.Y. Acad. Sci., 2004, 1014, 13
• [21] Lamberts S.W.J., Krenning E.P., Reubi J.C., Endocr. Rev., 1991, 12, 450[Crossref]
• [22] Pauwels S., et al., Semin. Oncol., 1994, 21, 15
• [23] Zimmer T., et al., Gut., 1994, 35, 471[Crossref]
• [24] Rieger A., et al., Neurosurg. Rev., 1997, 20, 7[Crossref]
• [25] Alexande H.R., et al., Ann. Surg., 1998, 228, 228[Crossref]
• [26] Berna L., et al., Eur. J. Nucl. Med., 1998, 25, 1482[Crossref]
• [27] Telischi E.F., et al., Otolaryngol. Head. Neck. Surg., 2000, 122, 358
• [28] Haslinghuis L.M., J. Endocrinol. Invest., 2001, 24, 415[Crossref]
• [29] Maina T., et al., Eur. J. Nucl. Med., 1994, 21, 437
• [30] Kolan H., Li J., Thakur M.L., Pept. Res., 1996, 9, 144
• [31] Decristoforo C., et al., Eur. J. Nucl. Med., 2000, 27, 1318[Crossref]
• [32] Gabriel M., et al., Q.J. Nucl. Med. Mol. Imag., 2005, 49, 237

Identyfikatory

DOI

10.1515/chem-2015-0042